CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Vascular Endothelial Growth Factor Is A Promising Therapeutic Target For The Treatment Of Clear Cell Carcinoma Of The Ovary
Authors
Deborah A. Altomare
Masami Hayashi
+3 more
Chiaki Kawase
Seiji Mabuchi
Kenichirou Morishige
Publication date
1 August 2010
Publisher
'Information Bulletin on Variable Stars (IBVS)'
Abstract
This study examines the role of vascular endothelial growth factor (VEGF) as a therapeutic target in clear cell carcinoma (CCC) of the ovary, which has been regarded as a chemoresistant histologic subtype. Immunohistochemical analysis using tissue microarrays of 98 primary ovarian cancers revealed that VEGF was strongly expressed both in early-stage and advanced-stage CCC of the ovary. In early-stage CCCs, patients who had tumors with high levels of VEGF had significantly shorter survival than those with low levels of VEGF. In vitro experiments revealed that VEGF expression was significantly higher in cisplatin-refractory human CCC cells (RMG1-CR and KOC7C-CR), compared with the respective parental cells (RMG1 and KOC7C) in the presence of cisplatin. In vivo treatment with bevacizumab markedly inhibited the growth of both parental CCC cell - derived (RMG1 and KOC7C) and cisplatin-refractory CCC cell - derived (RMG1-CR and KOC7C-CR) tumors as a result of inhibition of tumor angiogenesis. The results of the current study indicate that VEGF is frequently expressed and can be a promising therapeutic target in the management of CCC. Bevacizumab may be efficacious not only as a first-line treatment but also as a second-line treatment of recurrent disease in patients previously treated with cisplatin. ©2010 AACR
Similar works
Full text
Available Versions
University of Central Florida (UCF): STARS (Showcase of Text, Archives, Research & Scholarship)
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:stars.library.ucf.edu:scop...
Last time updated on 18/10/2022